Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
Purpose: To describe the characteristics of myopic choroidal neovascular membranes of hispanic subjects treated with a loading dose of Ranibizumab (Lucentis®). Study design: Non-randomized prospective observational case study. Methods: Five eyes of 5 patients with naïve CNV secondary to pathological...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | The Pan-American Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.thepajo.org/article.asp?issn=2666-4909;year=2017;volume=16;issue=2;spage=43;epage=45;aulast=Rios;type=0 |
| Summary: | Purpose: To describe the characteristics of myopic choroidal neovascular membranes of hispanic subjects treated with a loading dose of Ranibizumab (Lucentis®).
Study design: Non-randomized prospective observational case study.
Methods: Five eyes of 5 patients with naïve CNV secondary to pathological myopia were recruited for this study. Demographics, basal best-corrected visual acuity, grade of myopia, angiographic and tomographic features were obtained at baseline. A loading dose of three monthly Ranibizumab (Lucentis®) injections were given to the recruited subjects. After completion of the loading dose, a complete ophthalmological evaluation, angiography and spectral domain optical coherence tomography (SD-OCT) were obtained subsequently at six and twelve months of follow-up.
Results: The mean age of patients was 45 years. The mean spherical equivalent refractive error was -13.85. At baseline, the mean number of letters was 61.4 and at follow-up to 12 months the mean number of letters was 73.2. The central foveal thickness and subfoveal choroidal thickness decreased in all cases. After loading dose there was no persistent nor recurrent leakage from treated CNV on fluorescein angiography. FAF evidenced an increase in the area of atrophy, with a special circle pattern around the CNV.
Conclusions: This study showed a functional and morphologic improvement at 12 months in five Colombian subjects treated with a loading dose of 3 Ranibizumab monthly injections. |
|---|---|
| ISSN: | 2666-4909 2666-4909 |